Category: Covid-19 Vaccine

Page 266«..1020..265266267268..280290..»

The effect of the COVID-19 vaccination campaign on 250 cities in Israel – News-Medical.Net

March 22, 2022

A recent study posted to the Research Square* preprint server and under consideration at BMC Infectious Diseases assessed the impact of coronavirus disease 2019 (COVID-19) vaccines on unvaccinated populations and analyzed the various vaccination policies in Israel.

Various surveys have reported a stark decrease in new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Israel after 48% of its population was immunized against COVID-19. Understanding the parameters and variables that affected this decline in positive cases is important to formulate more effective COVID-19 policies.

The present observational study used daily demographics of SARS-CoV-2 cases and the economic data from 250 Israeli cities to investigate the impact of vaccination on unvaccinated populations. The researchers also studied the shift from the transition phase to the community-immunity phase observed in this country.

The team collected demographic data, including individual identification numbers, age, geographic area, date of polymerase chain reaction (PCR) test for COVID-19-diagnosis and test result, time of hospitalization, the worst hospital event, and COVID-19 outcome. Also, they obtained vaccination-related data like the number of vaccinations administered per day for different age groups and geographical areas. Additionally, data like the median age of a city population and the number of people belonging to each age group were collected.

The study defined two groups of populations, including the total population in a city and the populations susceptible to COVID-19 infections like the unvaccinated individuals and recovered COVID-19 patients. Furthermore, two important factors were also defined, namely the hospitalization impact factor and the positive impact factor.

An extended framework of the susceptible-exposed-infectious-removed (SEIR+) model was used to simulate COVID-19 transmission in Israel and the impact of vaccination policies on this spread. In this model, each person is represented by one out of the following range of states: susceptible (S), exposed (E), infected but pre-symptomatic (Ipre), infected and asymptomatic (Iasym), infected and symptomatic (Isym), recovered (R), hospitalized (H), fatal (F), quarantined and susceptible (Qs), quarantined and exposed (QE), quarantined and pre-symptomatic (Qpre), quarantined and asymptomatic (Qasym), quarantined and symptomatic (Qsym), and quarantined and recovered (QR). The transitions between each state were assessed from the known probabilities of COVID-19 in Israel.

The study also simulated vaccination policies having different vaccination rates. For each vaccination rate, four vaccination policies were simulated prioritizing the vaccination of:

1) younger populations,

2) older individuals,

3) people aged over 60 years, and

4) individuals aged between 16 and 35 years and then the rest of the populations; the last policy equally distributed vaccinations among all age groups.

The study results showed that from March 2020 and January 2021, a significant number of COVID-19-positive cases were observed in three SARS-CoV-2 infection waves. Also, an increase in cases was found in each subsequent wave. It was noted that when the vaccinations were first administered to the at-risk populations, there was a significant increase in the number of cases in the unvaccinated individuals, indicating the beginning of the transition phase. However, when 48% of the total population was vaccinated or COVID-19-recovered, a remarkable reduction in the number of cases was found across all the ages, suggesting the onset of the community-immunity phase.

The positive impact factor of the young population in comparison to the entire population (impactptot) and the susceptible population (impactpsus) was evaluated. The impactptot of 0.6 observed before the onset of vaccinations indicated that the positive ratio of the younger population was 60% as compared to the entire population. The impactptot reached 1.3 after the vaccinations started, which suggested that a higher number of unvaccinated individuals were infected.

The study noted that cities with populations of a lesser median age exhibited a reduction in new SARS-CoV-2 infections even when a lower percentage of total individuals were vaccinated as compared to the other cities. Furthermore, the entire country of Israel, having a median age of 30.5 years, had a similar decrease in new positive cases when 50% of the countrys population was vaccinated.

The simulation of four vaccination policies showed that the prioritization of vaccine administration and vaccination rate of a region play a significant role in the number of COVID-19 cases and related hospitalizations. The present model showed that simultaneously vaccinating individuals of all age groups is the most efficient vaccination policy against COVID-19.

The study findings showed that the age structure of a country plays a vital role in its COVID-19 vaccination policies. The study also highlighted the need to implement measures towards establishing community immunity across all populations. The researchers believed that this study can serve as a foundation for other countries for the development of effective COVID-19 policies.

Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Read the original post:

The effect of the COVID-19 vaccination campaign on 250 cities in Israel - News-Medical.Net

COVID-19 vaccine continues to be offered at clinics – oswegocountynewsnow.com

March 22, 2022

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Go here to see the original:

COVID-19 vaccine continues to be offered at clinics - oswegocountynewsnow.com

COVID-19 Vaccination and Psoriatic Arthritis – MD Magazine

March 22, 2022

John Tesser, MD: I want to dive into the waters of COVID-19 figuratively, clearly not absolutely. Lets start discussing COVID-19 vaccinations in patients with rheumatic and musculoskeletal diseases. Lets first touch on the importance of it and get into if its recommended. What are the potential problems? What are the difficulties and challenges we have in recommending them to our patients? Jen, how do you feel about the value of vaccination? Whats your understanding of how our field, through guidelines that have been coming down the pike, is advising us to recommend [the vaccine] to our patients?

Jennifer Simpson, DNP: Vaccinations are very important for our patient population. Their immune systems arent functioning the way they should be, so theyre at high risk for contracting these infections and having worse complications from them than someone without this type of disease. Vaccinations are definitely very important and should be reiterated and encouraged to our patients, and they should talk with their primary care providers about this as well. Its important to note to our patients that they may get a vaccine and it may not be as effective for them as the next person, which is why getting their [COVID] boosters and being on top of the timing with that are so important.

Generally speaking, were still understanding, and getting more information about how we need to make recommendations to our patients as far as how to take medicine, hold their medication, and how thats going to affect the vaccine efficacy. On our team weve been having patients hold their medications for a week after receiving their vaccine. What Ill often tell a patient whos on a once-a-week type of schedule, say with etanercept or with their methotrexate, is to get their flu shot and the COVID-19 vaccine on that date theyre due for their injection or pills. That way, theyre getting a week before or week after with their coverage, and hopefully that will be enough for them to mount some type of immune response.

That being said, in the general population, people think if they dont feel well after getting a vaccine, it caused them to be sick. [We need to] manage expectations with our patients, explaining to them you kind of want to feel unwell after getting a vaccine. Its telling your body youre mounting a response to what youve received. Youre building those antibodies, and thats what your immune system is doing when youre not feeling great after getting a vaccine. Thats what you want. Its working. A lot of people in the general population think thats a bad thing and that theyre getting sick and youre not, but its working.

I definitely think we need to encourage our patients and not make them feel unwelcome because you have certain patients for whom COVID-19 has been very polarizing, unfortunately, from a political standpoint. [We need to] take note of that for patients and not trying to make them feel uncomfortable in any sense. I always tell my patient, Its just my job to give you the expert opinion on whats going on and give you our viewpoint, but at the end of the day, its your decision. Its whatever you feel comfortable with because youre the one who has to live with the good, the bad, and the ugly of whatever happens. Its my job to tell you how it is, and from there you get to decide. Vaccines do go into that, especially with COVID-19, but we have to have a strong stance and really explain to patients why its so important for them to get it.

John Tesser, MD: You covered some very important points. Several of them got us through the guidelines that we have working for us. I totally agree with you. Your comments are in concert with what the ACR [American College of Rheumatology] guidance has been, and it has been changing over time. Theres a notion of things changing over time: we dont need masks, we need masks; you need to get your vaccine, maybe you dont need it, maybe it wont help you, etc. But thats how science works; everything changes. As you learn more, you change. The ACR definitely recommends to all our patients that they be vaccinated.

I agree: it needs to be a shared decision-making process. There are all kinds of reasons why people are hesitant about the vaccine, from the political, to the scared, to not wanting their disease to flare, to not believing it works, or thinking theyre going to grow 3 heads 10 years from now. But your approach is not to belittle patients, to ask them what their hesitancy is about it, and then to give them confidence. Some patients are confused because of all the misinformation and disinformation out there.

If they hear from their clinician that they recommend getting it, and now theyre hearing from their doctor, and youre a doctor too. We know that sways a lot of people in terms of their understanding. I take the stance and tell them Im a clinical immunologist. I do understand a fair amount about the immune system. We manipulate the immune system with our medicines. Vaccines are a brilliant mechanism to manipulate the system to teach it what COVID-19, the SARS-CoV-2 virus, looks like so it can recognize it. That it is a manner by which they can be protected, and that the American College of Rheumatology also advises it. You touched on holding their immunotherapies. We dont know the right answer to this. Weve been advised by the ACR with best guesses about what to do. In fact, were doing a study, called the COVER study, identifying patients who are ready to get boosters who are on these biologics and small-targeted molecules, to see if they hold their medicines and what their response will be after they get their booster shot. Were trying to figure this out. We dont know the answers. Were just flying by the seat of our pants as far as that goes.

This transcript has been edited for clarity.

See the rest here:

COVID-19 Vaccination and Psoriatic Arthritis - MD Magazine

Covid-19 news: Infection linked to higher risk of developing diabetes – New Scientist

March 22, 2022

By Michael Le Page, Clare Wilson, Jessica Hamzelou, Sam Wong, Graham Lawton, Adam Vaughan, Conrad Quilty-Harper, Jason Arunn Murugesu, Layal Liverpool, Carissa Wong, Alex Wilkins and Alexandra Thompson

A pharmacist checks a customers blood sugar levels

Getty Images

Covid-19 linked to a 46 per cent increased risk of type 2 diabetes

People who have had covid-19 within the past year may be more at risk of developing type 2 diabetes for the first time or being prescribed medication to manage their blood sugar levels.

Ziyad Al-Aly at the VA Saint Louis Health Care System in the US and his colleagues reviewed the medical records of 181,280 individuals who tested positive for covid-19 between March 2020 and September 2021, using data from the US Department of Veterans Affairs. The team compared the number of new diabetes cases among these veterans with that of more than 8 million people who had no evidence of a covid-19 infection. None of the participants had diabetes at the start of the study.

Covid-19 was linked to a 46 per cent higher risk of developing type 2 diabetes or requiring blood-sugar-lowering medication, even among people with a mild or asymptomatic covid-19 infection.

Type 2 diabetes occurs when the body cannot make enough insulin or the hormone that is produced does not work properly. SARS-CoV-2 virus may inflame insulin-producing cells, decreasing their efficiency, Al-Aly told The Washington Post.

The link between covid-19 and type 2 diabetes was observed among all the participant groups, regardless of their sex, ethnicity or age, said Al-Aly.

In August 2020, a different team uncovered a link between covid-19 and type 1 diabetes in children, with four NHS trusts in London seeing around double the usual number of new cases during the early months of the pandemic. Type 1 diabetes occurs when the body mistakenly attacks cells in the pancreas, causing no insulin to be produced.

Among adults, a team in Germany also recently linked covid-19 to a 28 per cent higher risk of type 2 diabetes.

Other coronavirus news

Pregnancy complications may be up to three times more likely among individuals who have tested positive for covid-19. Researchers analysed the medical records of 43,886 pregnant individuals in northern California between March 2020 and March 2021. Some pregnancy complications such as a preterm birth, clots and sepsis were up to three times more common among people who had a known covid-19 infection.

The most important thing people can do to protect themselves and their baby is to get vaccinated, co-author Mara Greenberg at The Permanente Medical Group said in a statement.

The number of people with covid-19 in Scottish hospitals has reached a record high, with 2128 cases on 20 March, surpassing the previous peak of 2053 in January. This comes after Scotland recently lifted many of its covid-19 restrictions. Not everyone with SARS-CoV-2 in hospital is necessarily admitted for covid-19.

Chinese officials have locked down 9 million people who live in the northeast city Shenyang amid the countrys current omicron wave. China reported 8024 cases yesterday.

Where did coronavirus come from? And other covid-19 questions answered

What is covid-19?

Covid-19 vaccines: Everything you need to know about the leading shots

Long covid: Do I have it, how long will it last and can we treat it?

Whats the fairest way to share covid-19 vaccines around the world?

Covid-19: The story of a pandemic

New Scientist Weekly features updates and analysis on the latest developments in the covid-19 pandemic. Our podcast sees expert journalists from the magazine discuss the biggest science stories to hit the headlines each week from technology and space, to health and the environment.

The Jump is a BBC Radio 4 series exploring how viruses can cross from animals into humans to cause pandemics. The first episode examines the origins of the covid-19 pandemic.

Why Is Covid Killing People of Colour? is a BBC documentary, which investigates what the high covid-19 death rates in ethnic minority patients reveal about health inequality in the UK.

Panorama: The Race for a Vaccine is a BBC documentary about the inside story of the development of the Oxford/AstraZeneca vaccine against covid-19.

Race Against the Virus: Hunt for a Vaccine is a Channel 4 documentary which tells the story of the coronavirus pandemic through the eyes of the scientists on the frontline.

The New York Times is assessing the progress in development of potential drug treatments for covid-19, and ranking them for effectiveness and safety.

Humans of COVID-19 is a project highlighting the experiences of key workers on the frontline in the fight against coronavirus in the UK, through social media.

Belly Mujinga: Searching for the Truth is a BBC Panorama investigation of the death of transport worker Belly Mujinga from covid-19, following reports she had been coughed and spat on by a customer at Londons Victoria Station.

Coronavirus, Explained on Netflix is a short documentary series examining the coronavirus pandemic, the efforts to fight it and ways to manage its mental health toll.

Stopping the Next Pandemic: How Covid-19 Can Help Us Save Humanity by Debora Mackenzie is about how the pandemic happened and why it will happen again if we dont do things differently in future.

The Rules of Contagion is about the new science of contagion and the surprising ways it shapes our lives and behaviour. The author, Adam Kucharski, is an epidemiologist at the London School of Hygiene and Tropical Medicine, UK, and in the book he examines how diseases spread and why they stop.

A Pfizer/BioNTech covid-19 vaccine injection

SYSPEO/SIPA/Shutterstock

The Pfizer/BioNTech vaccine is thought to have helped an immunocompromised person clear the covid-19 virus

Two doses of the Pfizer/BioNTech vaccine are thought to have cleared the SARS-CoV-2 virus from a person who first tested positive more than 7 months earlier. This is the first known time a covid-19 vaccine has been used to treat, rather than prevent, the infection.

Ian Lester has the rare genetic disease Wiskott-Aldrich syndrome, which weakens the immune system. Lester, 37, first tested positive for SARS-CoV-2 in December 2020. His immune system was unable to fight off the infection naturally for at least 218 days.

Given the persistent positive PCR tests and impact on his health and mental health, we decided on a unique therapeutic approach, said Stephen Jolles at Cardiff Universitys School of Medicine in a statement.

We administered two doses of the BioNTech Pfizer vaccine, one month apart, and very quickly saw a strong antibody response, much stronger than had been induced by the prolonged natural infection.

Lester was confirmed to have cleared SARS-CoV-2 72 days after the first vaccine dose and 218 days after his infection was detected.

To our knowledge, this is the first time mRNA vaccination has been used to clear persistent COVID-19 infection, said Mark Ponsford, at Cardiff University.

Other coronavirus news

England has rolled out a booster jab programme for people aged 75 and over, care home residents and people aged 12 and over who have a weakened immune system. The Office for National Statistics estimates one in 20 people in England had covid-19 in the week ending 12 March. It is hoped that the booster programme will protect people amid surging cases of the omicron BA.2 sublineage. Similar boosters are already being administered to some groups in Scotland and Wales.

China reported two covid-19 related deaths on 19 March, its first official covid-19 fatalities since January 2021. Both people died of underlying medical conditions, with mild covid-19 symptoms, according to Jiao Yahui at Chinas National Health Commission. The deaths occurred in the province Jilin, where more than two-thirds of the countrys cases have been reported amid its current covid-19 wave. On 19 March, Chinas reported new infections hit a rolling seven-day average of 2333 infections.

A police officer wearing personal protective equipment in Manzhouli, China

STR/AFP via Getty Images

Covid-19 is surging in China, with more than 5000 new cases a day

China yesterday reported 5280 new SARS-CoV-2 cases, more than double the previous days count and its highest daily tally since the start of the pandemic. The surge has prompted the introduction of full or partial lockdowns in various cities across the country.

China has been pursuing a strict zero covid strategy, which until recently had largely kept outbreaks under control. The omicron variant, however, is more transmissible than previous variants and is probably driving the current surge.

Cities across the country are now in full or partial lockdowns. The north-east province Jilin is the worst affected, accounting for more than 3000 of Chinas new reported cases on 15 March. Speaking on 14 March, Jilins governor vowed to achieve community zero-Covid in a week.

Chinas rising cases correspond with a global increase in SARS-CoV-2 transmission. A World Health Organization report reveals the number of new reported infections between 7 and 13 March increased by eight per cent compared to the previous week. The number of new weekly cases had been declining since the end of January.

Other coronavirus news

Face covering rules in Scotland will remain in place until April. On 15 March, Scotland reported 38,770 new covid cases, up from a daily average of 6,900 three weeks ago. As a result, coverings will continue to be required on public transport and in shops, although other covid restrictions will be lifted on 21 March. The BA.2 omicron sublineage, which is even more transmissible than the initial omicron variant, accounts for 80 per cent of Scotlands SARS-CoV-2 cases, according to first minister Nicola Sturgeon, who added it is prudent to keep mask rules in place. A small study has linked covid-19 with cardiovascular changes among unvaccinated people without any pre-existing medical conditions. Fbio Santos de Lira from So Paulo State University and his colleagues looked at 38 people, aged 20 to 40, less than six months after they were infected with SARS-CoV-2. Even mild or moderate infections were linked to cardiovascular changes that resulted in a raised heart rate, which affected some of the participantss ability to climb stairs or walk.

Commuters exit a London Overground train, Liverpool Street, London

AFP via Getty Images

Nearly 400,000 people in the UK tested positive for the coronavirus last week

Government statistics show 399,820 people tested positive for SARS-CoV-2 in the UK between 5 and 11 March, an increase of 143,956 (56.3 per cent) on the previous seven days. Between 1 and 7 March, hospitalisations increased by 16.9 per cent from the previous week. Deaths within 28 days of a positive test are rising more slowly, with a week-on-week increase of 2.8 per cent as of 11 March. Easing restrictions, waning immunity and the more transmissible omicron sublineage BA.2 are thought to be driving the surge in cases.

Amid the rise in infections, ministers have been criticised for scrapping Englands React study at the end of March. React randomly tests about 150,000 people across the country for SARS-CoV-2 each month to gauge nationwide infection levels. Talking to The Guardian, one scientist called the move about as far from following the science as you can get, while another accused ministers of turning off the headlights at the first sight of dawn.

Ministers are also being urged to consider offering older people a fourth vaccine dose. In England, people with a suppressed immune system, living in a care home or aged 75 or older are set to be offered an additional jab in April. Some scientists are calling for the age requirement to be set lower. However, a small Israeli study of healthcare workers found a fourth dose increased some antibody levels, but this did not translate into boosted immunity.

Other coronavirus news

Chinas covid-19 cases have doubled in 24 hours amid its worst outbreak in two years. Nearly 3400 new cases were reported on 13 March, double the previous day. This has prompted schools to shut in Shanghai, Chinas biggest city, and regional lockdowns to be introduced in several north-eastern hotspots. The surge in cases is thought to be driven by omicron and a rise in asymptomatic infections.

Latest on covid-19 from New Scientist

Many countries have scaled back their coronavirus restrictions, but Iceland is going further with a plan to let infections spread

Laboratory culture system using VeroE6 cells tested negative for covid-19.

Rockett et al, 2022

The monoclonal antibody sotrovimab has been linked to a drug-resistant mutation in SARS-CoV-2.

A study in Australia suggests that sotrovimab, a treatment for covid, may cause the coronavirus to acquire mutations that enable it to resist the drug.

Sotrovimab neutralises SARS-CoV-2s spike protein, which the virus uses to enter cells. Given through a drip, sotrovimab can be administered to people within five days of their infection to prevent symptoms from becoming severe.

Rebecca Rockett from the University of Sydney and her colleagues reviewed the first 100 people who received sotrovimab at a healthcare facility in New South Wales between August and November 2021, when the delta variant of the virus was dominant. Eight of the people who were treated persistently tested positive for SARS-CoV-2, and had airway samples collected before and after they received sotrovimab.

In four of these patients, SARS-CoV-2 developed spike mutations between six and 13 days after sotrovimab was administered, with these genetic changes making the drug effectively inactive, said Rockett, as reported in The Guardian.

The researchers are calling for increased genomic surveillance around sotrovimabs use. What we dont want to see is resistant virus disseminating in the community, because that will mean that a lot of other people cant use this drug as well, said Rockett.

Other coronavirus news

The WHO has warned the pandemic is far from over. The number of global recorded deaths between 28 February and 6 March declined by 8 per cent compared to the previous week, with recorded infections also falling by 5 per cent. Although reported cases and deaths are declining globally, and several countries have lifted restrictions, the pandemic is far from over and it will not be over anywhere until its over everywhere, Tedros Adhanom Ghebreyesus, WHOs director-general, said on 9 March. The virus continues to evolve, and we continue to face major obstacles in distributing vaccines, tests and treatments everywhere they are needed.

A surveillance programme that looks for SARS-CoV-2 in wastewater has been rolled out across Northern Ireland, the BBC reported. Wastewater samples from 31 sites are being collected every day and sent to a Queens University Belfast laboratory for testing. Gauging infection levels in specific areas may help to prevent large SARS-CoV-2 outbreaks, with the technology also looking for new variants.

Students queuing up for covid-19 nucleic acid tests, Qingdao, Shandong province, China

Wei Zhe/VCG via Getty Images

Covid deaths and new infections are continuing to decline after the peak of the omicron surge

The number of global recorded covid deaths between 28 February and 6 March declined by 8 per cent compared to the previous week. In its weekly update, the WHO reported the number of recorded new SARS-CoV-2 infections also decreased by 5 per cent week-on-week.

In the week starting 28 February, more than 10 million new covid cases and 52,000 deaths were reported across the WHOs six regions.

Case numbers only increased in the Western Pacific Region, rising by 46 per cent. Covid deaths rose in the Western Pacific and Eastern Mediterranean regions, by 29 per cent and 2 per cent, respectively, with fatalities falling elsewhere.

The surge in infection caused by the omicron variant appears to have peaked in February. But the WHO has stressed that countries vary in their testing strategies and therefore any trends should be interpreted with caution.

Other coronavirus news

However, in the UK, reported coronavirus cases have increased by nearly two-fifths week-on-week. According to government data,322,917 people reported a positive test between 2 and 8 March, an increase of 90,944 (39.2 per cent) from the previous week. Hospital covid admissions are also rising, with 8763 people admitted between 26 February and 4 March, an increase of 11.1 per cent from the previous week. Deaths have slightly declined, however. Between 2 and 8 March, 729 people died within 28 days of a positive test, 12 (1.6 per cent) fewer than the previous week.

The number of cancer research studies funded in the UK fell by 32 per cent in the first year of the pandemic, according to figures from the National Cancer Research Institute. The money awarded to these projects plunged by 57 per cent, The Guardian reports. The closing of charity shops and cancelled fundraising events are thought to have contributed to the problem.

Covid-19 booster jab information campaign, Putney, London, UK

Amer Ghazzal/Shutterstock

Booster jabs substantially increased protection against omicron but efficacy starts to fall after two months

The protection given by vaccine booster shots against the omicron variant starts to decline after two months, a study has found.

Researchers at the UK Health Security Agency looked at covid-19 infections in the UK between 27 November 2021 and 12 January 2022 the period in which the omicron variant started to spread widely. The data included over one million people who had been infected with either the delta or omicron variant.

The researchers only looked at whether people developed a mild illness and not whether someone was hospitalised or not.

They found that a booster dose substantially increased protection against developing mild illness from the omicron variant. Two doses of the Pfizer/BioNTech vaccine were only 8.8 per cent effective against the omicron variant after 25 or more weeks. But a third booster dose of this vaccine increased protection to 67.2 per cent. However, this then dropped to 45.7 per cent after 10 or more weeks.

A Moderna booster, given to those who had received two initial doses of the Pfizer jab, was 73.9 per cent effective against mild illness from the omicron variant after two to four weeks. This then dropped to 64.4 per cent after five to nine weeks.

Go here to read the rest:

Covid-19 news: Infection linked to higher risk of developing diabetes - New Scientist

Counties with the highest COVID-19 vaccination rate in New Mexico – KRQE News 13

March 22, 2022

(STACKER) The vaccine deployment in December 2020 signaled a turning point in the COVID-19 pandemic. By theend of May 2021, 40% of the U.S. population was fully vaccinated. But as vaccination rates lagged over the summer, new surges of COVID-19 came, including Delta in the summer of 2021, and now the Omicron variant, which comprises themajority of casesin the U.S.

Researchers around the world have reported that Omicron ismore transmissiblethan Delta, making breakthrough and repeat infections more likely. Early research suggests this strain may cause less severe illness than Delta and the original virus, however, health officials have warned an Omicron-driven surge could stillincrease hospitalization and death ratesespecially in areas with less vaccinated populations.

The United States as of March 18 reached 970,343 COVID-19-related deaths and nearly 79.7 million COVID-19 cases, according toJohns Hopkins University.Currently, 65.3% of the population isfully vaccinated, and 44.4% of vaccinated people have received booster doses.

Stackercompiled a list of the counties with highest COVID-19 vaccination rates in New Mexico using data from theU.S. Department of Health & Human ServicesandCovid Act Now. Counties are ranked by the highest vaccination rate as of March 17, 2022. Due to inconsistencies in reporting, some counties do not have vaccination data available. Keep reading to see whether your county ranks among the highest COVID-19 vaccination rates in your state.

Population that is fully vaccinated: 36.0% (6,651 fully vaccinated) 48.6% lower vaccination rate than New Mexico Cumulative deaths per 100k: 497 (92 total deaths) 46.6% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 26,930 (4,982 total cases) 9.5% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 39.7% (6,136 fully vaccinated) 43.4% lower vaccination rate than New Mexico Cumulative deaths per 100k: 336 (52 total deaths) 0.9% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 17,230 (2,664 total cases) 30.0% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 39.7% (6,136 fully vaccinated) 43.4% lower vaccination rate than New Mexico Cumulative deaths per 100k: 336 (52 total deaths) 0.9% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 17,230 (2,664 total cases) 30.0% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 40.4% (28,709 fully vaccinated) 42.4% lower vaccination rate than New Mexico Cumulative deaths per 100k: 447 (318 total deaths) 31.9% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 26,971 (19,168 total cases) 9.6% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 41.4% (1,460 fully vaccinated) 40.9% lower vaccination rate than New Mexico Cumulative deaths per 100k: 369 (13 total deaths) 8.8% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 11,710 (413 total cases) 52.4% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 41.8% (24,441 fully vaccinated) 40.4% lower vaccination rate than New Mexico Cumulative deaths per 100k: 453 (265 total deaths) 33.6% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 29,051 (16,983 total cases) 18.1% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 42.7% (3,521 fully vaccinated) 39.1% lower vaccination rate than New Mexico Cumulative deaths per 100k: 594 (49 total deaths) 75.2% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 24,052 (1,985 total cases) 2.2% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 45.3% (30,584 fully vaccinated) 35.4% lower vaccination rate than New Mexico Cumulative deaths per 100k: 267 (180 total deaths) 21.2% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 19,716 (13,306 total cases) 19.9% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 46.0% (1,866 fully vaccinated) 34.4% lower vaccination rate than New Mexico Cumulative deaths per 100k: 370 (15 total deaths) 9.1% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 19,192 (779 total cases) 22.0% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 46.4% (22,702 fully vaccinated) 33.8% lower vaccination rate than New Mexico Cumulative deaths per 100k: 376 (184 total deaths) 10.9% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 25,604 (12,534 total cases) 4.1% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 46.7% (817 fully vaccinated) 33.4% lower vaccination rate than New Mexico Cumulative deaths per 100k: 286 (5 total deaths) 15.6% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 32,609 (570 total cases) 32.6% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 48.3% (302 fully vaccinated) 31.1% lower vaccination rate than New Mexico Cumulative deaths per 100k: 640 (4 total deaths) 88.8% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 12,960 (81 total cases) 47.3% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 51.4% (2,157 fully vaccinated) 26.7% lower vaccination rate than New Mexico Cumulative deaths per 100k: 333 (14 total deaths) 1.8% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 25,869 (1,086 total cases) 5.2% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 52.9% (10,355 fully vaccinated) 24.5% lower vaccination rate than New Mexico Cumulative deaths per 100k: 327 (64 total deaths) 3.5% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 26,431 (5,173 total cases) 7.4% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 54.2% (41,546 fully vaccinated) 22.7% lower vaccination rate than New Mexico Cumulative deaths per 100k: 330 (253 total deaths) 2.7% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 24,031 (18,429 total cases) 2.3% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 57.6% (6,873 fully vaccinated) 17.8% lower vaccination rate than New Mexico Cumulative deaths per 100k: 536 (64 total deaths) 58.1% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 20,224 (2,415 total cases) 17.8% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 57.8% (9,608 fully vaccinated) 17.5% lower vaccination rate than New Mexico Cumulative deaths per 100k: 517 (86 total deaths) 52.5% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 22,726 (3,781 total cases) 7.6% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 58.1% (2,627 fully vaccinated) 17.1% lower vaccination rate than New Mexico Cumulative deaths per 100k: 354 (16 total deaths) 4.4% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 16,678 (754 total cases) 32.2% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 60.1% (16,027 fully vaccinated) 14.3% lower vaccination rate than New Mexico Cumulative deaths per 100k: 667 (178 total deaths) 96.8% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 25,953 (6,923 total cases) 5.5% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 60.8% (16,578 fully vaccinated) 13.3% lower vaccination rate than New Mexico Cumulative deaths per 100k: 191 (52 total deaths) 43.7% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 21,102 (5,756 total cases) 14.2% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 61.2% (16,533 fully vaccinated) 12.7% lower vaccination rate than New Mexico Cumulative deaths per 100k: 296 (80 total deaths) 12.7% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 24,506 (6,616 total cases) 0.4% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 61.3% (6,616 fully vaccinated) 12.6% lower vaccination rate than New Mexico Cumulative deaths per 100k: 649 (70 total deaths) 91.4% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 18,729 (2,021 total cases) 23.9% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 61.7% (2,651 fully vaccinated) 12.0% lower vaccination rate than New Mexico Cumulative deaths per 100k: 395 (17 total deaths) 16.5% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 25,581 (1,100 total cases) 4.0% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 62.5% (136,428 fully vaccinated) 10.8% lower vaccination rate than New Mexico Cumulative deaths per 100k: 330 (719 total deaths) 2.7% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 28,692 (62,605 total cases) 16.6% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 63.4% (78,578 fully vaccinated) 9.6% lower vaccination rate than New Mexico Cumulative deaths per 100k: 591 (733 total deaths) 74.3% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 32,649 (40,471 total cases) 32.7% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 64.1% (435,069 fully vaccinated) 8.6% lower vaccination rate than New Mexico Cumulative deaths per 100k: 252 (1,711 total deaths) 25.7% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 21,487 (145,923 total cases) 12.7% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 64.2% (94,165 fully vaccinated) 8.4% lower vaccination rate than New Mexico Cumulative deaths per 100k: 266 (390 total deaths) 21.5% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 22,645 (33,231 total cases) 7.9% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 64.5% (15,287 fully vaccinated) 8.0% lower vaccination rate than New Mexico Cumulative deaths per 100k: 515 (122 total deaths) 51.9% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 28,188 (6,683 total cases) 14.6% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 68.2% (48,656 fully vaccinated) 2.7% lower vaccination rate than New Mexico Cumulative deaths per 100k: 806 (575 total deaths) 137.8% more deaths per 100k residents than New Mexico Cumulative cases per 100k: 35,968 (25,669 total cases) 46.2% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 68.5% (26,646 fully vaccinated) 2.3% lower vaccination rate than New Mexico Cumulative deaths per 100k: 331 (129 total deaths) 2.4% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 24,938 (9,706 total cases) 1.4% more cases per 100k residents than New Mexico

Population that is fully vaccinated: 71.5% (13,855 fully vaccinated) 2.0% higher vaccination rate than New Mexico Cumulative deaths per 100k: 67 (13 total deaths) 80.2% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 13,940 (2,700 total cases) 43.3% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 71.5% (107,511 fully vaccinated) 2.0% higher vaccination rate than New Mexico Cumulative deaths per 100k: 172 (259 total deaths) 49.3% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 18,653 (28,047 total cases) 24.2% less cases per 100k residents than New Mexico

Population that is fully vaccinated: 73.0% (23,901 fully vaccinated) 4.1% higher vaccination rate than New Mexico Cumulative deaths per 100k: 272 (89 total deaths) 19.8% less deaths per 100k residents than New Mexico Cumulative cases per 100k: 16,160 (5,288 total cases) 34.3% less cases per 100k residents than New Mexico

Read more from the original source:

Counties with the highest COVID-19 vaccination rate in New Mexico - KRQE News 13

SK Bioscience to supply homegrown Covid-19 vaccine to KDCA – KBR

March 22, 2022

SK Bioscience said Monday that it signed a supply contract of GBP510, an independently developed Covid-19 vaccine candidate, with the Korea Disease Control and Prevention Agency (KDCA).

The contract amount is for 10 million doses, and SK Bioscience will supply them sequentially according to the inoculation plan of the KDCA after completing the development of GBP510.

SK Bioscience said that the company has proven its world-class technology by consigning and supplying two of the five major Covid-19 vaccines -- AstraZeneca and Novavax -- licensed in from advanced countries, such as the U.S. and EU, and receiving approval to supply its vaccine.

Based on such experiences, SK Bioscience plans to provide a new Covid-19 vaccine option through the supply of GBP510 and contribute to the national goal of preparing for an endemic era by securing vaccine sovereignty without being swayed by global supply-demand volatility while leading the successful globalization of Korean-made vaccines in the global market.

The company also seeks to promote the Korean vaccine industry into a global vaccine hub by providing GBP510 as a control vaccine to other Korean vaccine developers after consultation with health authorities.

"The GBP510 is the result of SK's technological prowess, the government's will to become a bio powerhouse, and the cooperation of global organizations supporting vaccine development for the public's right to health," SK Bioscience CEO Ahn Jae-yong said. "Starting with GBP510, we will develop products to prepare for various viral infections and establish ourselves as a leading company in the global vaccine market."

SK Bioscience developed GBP510 jointly with the University of Washington's Institute for Protein Design and used GSK's adjuvants in the clinical trials.

GBP510 is undergoing a global phase 3 clinical trial to verify safety and effectiveness. SK Bioscience has recently started expanding the scope of vaccination through additional clinical trials.

The company aims to expand the scope of the vaccine to include booster shots and children and adolescents simultaneously as part of its efforts to commercialize GBP510.

SK Bioscience has started research to confirm the preventive effect of GBP510 on Covid-19 variants, such as Omicron. It is building a platform to respond to the next pandemic using GBP510 development technology.

The company recently confirmed that the booster shot showed a preventive effect on Omicron virus from participants in the GBP510 phase 1 and 2 clinical trials and is conducting a comprehensive study.

SK Bioscience is also looking into developing a vaccine targeting the sarbecovirus, including Covid-19 and SARS (severe acute respiratory syndrome) viruses and related variants.

Read the original post:

SK Bioscience to supply homegrown Covid-19 vaccine to KDCA - KBR

New York City mayor says Nets, Knicks, Yankees, Mets will have to wait for loosened COVID-19 vaccination restrictions – ESPN

March 22, 2022

NEW YORK -- New York Mayor Eric Adams reiterated that while he remains optimistic about the COVID 19-related numbers he's seeing, the city's professional sports teams are going to have to wait their turn as far as potential vaccination-mandate rollbacks are concerned.

"Right now, we're going to take some complaints," Adams said during a Tuesday morning news conference announcing that masks will be optional for day care students between the ages of 2 and 4 starting on April 4 if the COVID numbers hold. "But when this is all said and done, people are going to realize this is a thoughtful administration and we got it right. So baseball, basketball, businesses, all of those things, they have to wait until that layer comes."

The layer that teams like the Brooklyn Nets, New York Knicks, New York Yankees and New York Mets are all waiting on is a rollback of the private employer mandate, which does not allow employees to work in the office -- or in this case players to play for their teams -- if they are not vaccinated against COVID. Nets star guard Kyrie Irving, who is not vaccinated and has made it clear he won't get the vaccine, has not been able to play in any games in New York City this season because of the mandate.

"We're going to do it in the right way," Adams said. "We're going to follow the science ... we're going to make the right decision. And in New York, no matter what you do, this is 8.8 million people and 30 million opinions, so you're never going to satisfy New Yorkers, so you must go with the logic, your heart and the science."

2 Related

For Adams, that means he will continue to listen to his medical team and doesn't sound likely to be swayed by any of the professional teams that might be impacted. The Yankees' home opener is April 7, the NBA play-in tournament starts April 12 and the Mets' home opener is April 15.

When asked if he has felt heat from local sports teams to pull back the mandate, Adams said he doesn't "feel any pressure doing this job at all, because I'm going to do what's right." He said one of the main reasons he doesn't feel pressed is because of his experience as a New York City transit cop in the 1980s.

"We're going to slowly peel back, as I stated over and over again, we're going to do it layer by layer and each layer we peel back we're going to do an analysis: 'Are we OK?'" Adams said. "And if we have to pivot and shift and come back here in a week and say we're going to do something different, we're going to do that. I'm not going to hesitate to say this is where the numbers are taking us, this is where the science is and this is what we're going to do. Because I'm not going to only view this from where we are in the crisis, I see myself out of crisis.

"And people are going to look back later like they did with the schools -- remember what they did to us when we were talking about keeping the schools open -- I said, 'Don't worry about the noise, team, we're going to do the right thing for our children' and people are going to look back later and say, 'You know what? We don't want to admit it, but this administration got it right, and they're going to do that again.'"

Adams said the feedback he's gotten from local businesses is that they appreciate the mandate remaining in place.

"Believe it or not, a lot of our businesses, they love the mandates," Adams said. "When I speak to a lot of my businesses, getting people back in the office, that mandate is allowing them to feel safe in the office for those who feel that they would rather the vaccine mandate to be in place. But again, we're going to do it in layers, and when we feel it's the right time to look at that, if we do so at all, because the work environment is an important environment, we're going to make that determination. We're not there yet."

New York City's infection rate has been climbing again lately, rising 50% over the past week. The city is averaging a little more than 950 new cases per day, comparable to the daily average in early November before the start of the omicron wave.

City health commissioner Ashwin Vasan said cases have increased slightly in recent days and officials will continue to watch the trends over the next two weeks before deciding whether to lift the rule.

Vasan said officials are closely monitoring the spread of a strain of the more transmissible omicron subvariant known as BA.2 and expect to see rising cases to some degree.

Information from The Associated Press was used in this report.

Visit link:

New York City mayor says Nets, Knicks, Yankees, Mets will have to wait for loosened COVID-19 vaccination restrictions - ESPN

Heres the latest on possible 4th COVID-19 vaccine shot for Americans – OregonLive

March 21, 2022

Will American adults have access to a fourth shot of COVID-19 vaccine? Drugmaker Moderna has asked the Food and Drug Administration to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults.

However, rival pharmaceutical company Pfizers request was approval for a booster shot for only seniors.

U.S. officials have been laying the groundwork to deliver additional booster doses to shore up the vaccines protection against serious disease and death from COVID-19. The White House has been sounding the alarm that it needs Congress to urgently approve more funding for the federal government to secure more doses of the COVID-19 vaccines, either for additional booster shots or variant-specific immunizations.

U.S. health officials currently recommend a primary series of two doses of the Moderna vaccine and a booster dose months later.

Moderna said its request for an additional dose was based on recently published data generated in the United States and Israel following the emergence of Omicron.

Last Tuesday, Pfizer and its partner BioNTech asked U.S. regulators to authorize an additional booster dose of their COVID-19 vaccine for seniors.

The New York-based drugmaker and its German partner BioNTech SE said that they have sought an emergency-use authorization for a second booster of their vaccine, Comirnaty, for people 65 and older who have already received a booster of any of the authorized COVID-19 vaccines.

Pfizer and BioNTech said they submitted data to the FDA from Israel, which began offering a fourth shot to older people and health-care workers last year as the omicron variant was circulating.

In a press release announcing its application to the FDA, Pfizer said an analysis of Israeli medical records showed that the rate of confirmed infections in people 60 and older who received a second booster was half that seen in their counterparts who had had only three doses of the vaccine. In addition, the likelihood of developing severe COVID-19 was four times lower in the group that got a second booster, the company said.

Pfizers FDA application also included results of an unspecified clinical trial in which it offered a second booster shot to Israeli health care workers who wanted it. Among the 154 workers who got the fourth shot, neutralizing antibodies rose by a factor of seven to eight, and antibodies specific to the omicron variant increased by a factor of eight to 10, Pfizer said.

While the study design and names of researchers conducting the trial are unclear in Pfizers press release, these findings appear to reflect a segment of the population that was the subject of Wednesdays New England Journal of Medicine study.

As vaccine experts await a fuller account of the data cited by Pfizer, they pointed to the newly published Israeli study as evidence that any discussion of second-booster-for-all is premature.

In the U.S., people 12 and older can receive a single booster dose of the Comirnaty vaccine if theyve already completed the two dose Pfizer-BioNTech regimen. Among those who initially got a shot developed by Moderna Inc. or Johnson & Johnson, only those 18 and older can get a Comirnaty booster.

People who received a third dose generally fared better against the delta and omicron variants than people who received only two doses, according to studies the Centers for Disease Control and Prevention released earlier this year.

While COVID-19 cases have dropped sharply from their winter peak, there are signs that another increase in infections could be in the cards in the coming weeks. More than a third of CDC wastewater sample sites in the U.S. showed rising virus trends earlier this month.

Pfizer is also studying an omicron-specific vaccine and a hybrid shot that would target omicron along with earlier variants. The company is expected to report data on these efforts in April.

The CDC recommends some immunocompromised people get a three-dose primary series of mRNA shots and a fourth shot as a booster.

Dr. Paul Offit, an infectious-disease expert at Childrens Hospital of Philadelphia, said that for older and sicker Americans, three shots of vaccine should probably be considered the primary series. The case for a possible fourth shot a booster for these Americans has yet to be made, he added.

In most people, two to three doses or mRNA vaccine have virtually eliminated the threat of an infection progressing to severe disease or death, Offit said. It will be difficult to demonstrate that the immune system needs more vaccine to protect itself against the SARS-CoV-2 virus, he added.

If were going to get past this pandemic, we need to realize that protection against mild illness will not be long-lived, Offit said. Key to that is acknowledging that infections that amount to little more than a sniffle and a cough dont warrant strenuous efforts to prevent. As long as protection against serious illness holds up, we should consider that a win, he said.

--The Associated Press, Bloomberg News and Los Angeles Times contributed to this report

More here:

Heres the latest on possible 4th COVID-19 vaccine shot for Americans - OregonLive

Here’s the latest on COVID-19 vaccines for the youngest kids – Futurity: Research News

March 18, 2022

At a high level, the Moderna, Pfizer, and J&J vaccines are all giving instructions to our cells to produce one of the SARS-CoV-2 proteins, the spike protein. Our immune systems then learn to target that spike protein as foreign. When the SARS-CoV-2 virus hits us, the immune system is already prepared with the tools for defense. It attacks the spike protein and keeps you from getting sick, or at least from getting as sick as you would have if you werent vaccinated.

The Novavax is similar to more traditional vaccines in its technology, but it works along similar lines as the described COVID-19 vaccines. The key difference is the Novavax vaccine is the SARS-CoV-2 spike protein itself, not the instructions for how to make it.

It is just the proteinnot a live or inactivated virus. The vaccine is relatively easy to distribute, because the cold chain requirements are not as strict as for the mRNA and adenovirus-vectored vaccines [such as the Moderna, Pfizer, and J&J vaccines]. If someone is allergic to the mRNA vaccines, they may not be to the Novavax, as it does not contain polyethylene glycol [an ingredient used as a stabilizing agent in some COVID-19 vaccines]. It appears to be highly effective against all the variants weve seen so far.

(As a side note, the Novavax vaccine is made using moth cells to generate the protein and tree bark for an ingredient to boost immune response. There are other vaccines based on particles derived from tobacco plants. Nature is an amazing thing, and I think we will find the work on vaccines over the last couple of years will allow science to solve problems that we couldnt before.)

Visit link:

Here's the latest on COVID-19 vaccines for the youngest kids - Futurity: Research News

Covid Live Updates: N.Y.C. Reports Spread of BA.2 Version of Omicron – The New York Times

March 18, 2022

A coronavirus testing site this month, outside a Hong Kong residential building under lockdown.Credit...Billy H.C. Kwok for The New York Times

Hong Kong said that more than one million people in the city of 7.5 million had tested positive for the coronavirus since the beginning of the pandemic, a worrying milestone for a city being battered by an extraordinarily lethal Omicron wave.

Hong Kong health officials said in a news conference on Friday that they had recorded 20,082 daily new cases and 206 new deaths, bringing the cumulative totals to more than 1,010,000 cases and more than 5,000 deaths.

Source: Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. The daily average is calculated with data that was reported in the last seven days.

While other places in Asia like China, South Korea, Thailand and Vietnam are experiencing similar case waves driven by Omicron, Hong Kongs death rate is high, far outstripping that of mainland China, which has reported a total of about 4,600 deaths in a population of over 1.4 billion. Almost 95 percent of the citys deaths have come in the past 30 days, government data show.

Hong Kong was once viewed as a world leader in controlling the coronavirus crisis. But despite limits on public gatherings, restrictions on nighttime dining and mask mandates, a wave of Omicron cases that began late last year has overwhelmed its health care system, leading to bodies of the dead being piled up in hospitals.

In the past two weeks, Hong Kong has recorded about 65 percent of cases that it has ever had, government data show. Experts have said that figure is most likely an undercount. Using models, researchers at the University of Hong Kong estimated this week that at least 3.6 million people had been infected. Up to 4.5 million people may get the virus before the current outbreak ends, they added.

The outbreak involves the BA.2 subvariant of Omicron, which is more transmissible than Omicrons first version, BA.1, though not necessarily more virulent. Researchers in Britain and Denmark have found that BA.2 is no more likely to cause hospitalizations, but studies elsewhere are ongoing.

Other factors in Hong Kongs surge are also at play: The city is densely populated, and has a low vaccination rate among those 70 and older and residents of nursing homes. Its success in keeping the virus at bay until recently has also left many residents without any enhanced immunity.

Hong Kongs government is caught between the surging cases and deaths, pressure from Beijing for mass testing and lockdowns, and pandemic fatigue among residents. On Thursday, Carrie Lam, the citys chief executive, said at a news conference that she would move up the review of its current measures planned for April 20 to as soon as next week and reconsider its flight bans, compulsory testing and mandatory quarantines for travelers. I have a very strong feeling that peoples tolerance is fading, she said.

Hong Kongs case data included results from rapid antigen tests, officials said, which the government has accepted in lieu of P.C.R. test results since last month to expand testing capacity. Residents who test positive with rapid antigen tests have not had to seek confirmation with P.C.R. tests. But the government has also asked them to self-report their infections, or face legal consequences. Those who receive a positive result from a rapid antigen test may be randomly requested to be administered a P.C.R. test, officials said.

At a news conference on Friday, Ms. Lam underscored the urgency of reporting home tests to health authorities. If there are people blatantly refusing to comply, then isnt it incumbent upon the law enforcement body to do something? she said.

Johns Hopkins Universitys Center for Systems Science and Engineering, which has supplied the raw numbers for Our World in Data and The New York Timess coronavirus world map, has reported fewer cases than the Hong Kong government.

Source: Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. The daily average is calculated with data that was reported in the last seven days.

The difference is because the center has not been including results from the citys rapid antigen tests in its total, but in an email on Friday, it said it intended to incorporate them in the future.

See the original post:

Covid Live Updates: N.Y.C. Reports Spread of BA.2 Version of Omicron - The New York Times

Page 266«..1020..265266267268..280290..»